This product belongs to the macrolide antibiotics. It has antibacterial activity against Staphylococcus (except methicillin-resistant strains), various groups of streptococci and Gram-positive bacilli. Neisseria, Haemophilus influenzae, Bordetella pertussis, etc. are also sensitive to this product. This product also has antibacterial effects on various anaerobic bacteria except Bacteroides fragilis and Fusobacterium. It also has inhibitory effects on Legionella, Campylobacter fetus, certain spirochetes, Mycoplasma pneumoniae, Rickettsia and Chlamydia. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor site ("P" site), blocking the transfer RNA (t-RNA) from binding to the "P" site, and also blocking the displacement of the polypeptide chain from the acceptor site ("A" site) to the "P" site, thereby inhibiting bacterial protein synthesis.

This product is a nitroimidazole derivative that can inhibit the redox reaction of amoeba and break the nitrogen chain of the protozoa. In vitro tests have shown that when the drug concentration is 1~2mg/L, the histolytica amoeba can undergo morphological changes in 6~20 hours and all are killed within 24 hours. When the concentration is 0.2mg/L, the histolytica amoeba can be killed within 72 hours. This product has a strong effect of killing trichomonas, and its mechanism is unknown. Metronidazole has a killing effect on cells and anaerobic microorganisms growing under hypoxic conditions. The metabolites generated when it is reduced in the human body also have anti-anaerobic effects, inhibiting the synthesis of bacterial deoxyribonucleic acid, thereby interfering with the growth and reproduction of bacteria, and ultimately causing bacterial death.

This product is the levorotatory form of tetramisole, which can selectively inhibit succinate dehydrogenase in the muscles of the worm, so that fumaric acid cannot be reduced to succinic acid, thereby affecting the anaerobic metabolism of the muscles of the worm and reducing energy production. When the worm comes into contact with it, it can depolarize the nerves and muscles, and the muscles will continue to contract and cause paralysis; the drug's cholinergic effect is conducive to the excretion of the worm. Its activity is about 1 to 2 times that of tetramisole (racemic form), but its toxic side effects are lower. In addition, the drug may have an inhibitory effect on the microtubule structure of the worm. Levamisole also has immune regulation and immune excitation functions.

This product can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects

This product can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects.

This product can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects.

This product can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects

This product can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects.

This product can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects.